Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPORT: Robot-Assisted Aspiration and Tenecteplase for PH2 Hemorrhagic Transformation
NCT07641998Phase 1Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenecteplase in hemorrhagic transformation of ischemic stroke (HT), sponsored by Beijing Tiantan Hospital. Primary endpoints: Symptomatic rebleeding rate at 72 hours, Target hematoma reduction rate at 7 days and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
hemorrhagic transformation of ischemic stroke (HT)
Beyond the preview
Go deeper on NCT07641998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641998.